These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 27198680)

  • 1. Angiographic and Clinical Outcomes After Everolimus-Eluting Stenting for Unprotected Left Main Disease and High Anatomic Coronary Complexity.
    Migliorini A; Valenti R; Parodi G; Vergara R; Buonamici P; Cerisano G; Carrabba N; Antoniucci D
    JACC Cardiovasc Interv; 2016 May; 9(10):1001-7. PubMed ID: 27198680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiographic and clinical outcome after crush of everolimus-eluting stent for distal unprotected left main disease.
    Migliorini A; Valenti R; Vergara R; Grazia De Gregorio M; Gabrielli E; De Vito E; Raffaella Aicale M; Carrabba N; Antoniucci D
    Catheter Cardiovasc Interv; 2017 Jul; 90(1):72-77. PubMed ID: 28707445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
    Tiroch K; Mehilli J; Byrne RA; Schulz S; Massberg S; Laugwitz KL; Vorpahl M; Seyfarth M; Kastrati A;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):29-36. PubMed ID: 24332416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anatomic- and clinical-based NERS (new risk stratification) score II to predict clinical outcomes after stenting unprotected left main coronary artery disease: results from a multicenter, prospective, registry study.
    Chen SL; Han YL; Zhang YJ; Ye F; Liu HW; Zhang JJ; Xu B; Jiang TM; Zhou YJ; Lv SZ
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1233-41. PubMed ID: 24239199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease).
    Ribichini F; Romano M; Rosiello R; La Vecchia L; Cabianca E; Caramanno G; Milazzo D; Loschiavo P; Rigattieri S; Musarò S; Pironi B; Fiscella A; Amico F; Indolfi C; Spaccarotella C; Bartorelli A; Trabattoni D; Della Rovere F; Rolandi A; Beqaraj F; Belli R; Sangiorgio P; Villani R; Berni A; Sheiban I; Lopera Quijada MJ; Cappi B; Ribaldi L; Vassanelli C;
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1012-22. PubMed ID: 24055444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of 3-dimensional bifurcation angle on 5-year outcome of patients after percutaneous coronary intervention for left main coronary artery disease: a substudy of the SYNTAX trial (synergy between percutaneous coronary intervention with taxus and cardiac surgery).
    Girasis C; Farooq V; Diletti R; Muramatsu T; Bourantas CV; Onuma Y; Holmes DR; Feldman TE; Morel MA; van Es GA; Dawkins KD; Morice MC; Serruys PW
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1250-60. PubMed ID: 24355115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term clinical and angiographic outcomes of percutanenous coronary intervention with everolimus-eluting stents for the treatment of cardiac allograft vasculopathy.
    Cheng R; Vanichsarn C; Patel JK; Currier J; Chang DH; Kittleson MM; Makkar R; Kobashigawa JA; Azarbal B
    Catheter Cardiovasc Interv; 2017 Jul; 90(1):48-55. PubMed ID: 27862865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term prognostic value of risk scores after drug-eluting stent implantation for unprotected left main coronary artery: A pooled analysis of the ISAR-LEFT-MAIN and ISAR-LEFT-MAIN 2 randomized clinical trials.
    Xhepa E; Tada T; Kufner S; Ndrepepa G; Byrne RA; Kreutzer J; Ibrahim T; Tiroch K; Valgimigli M; Tölg R; Cassese S; Fusaro M; Schunkert H; Laugwitz KL; Mehilli J; Kastrati A
    Catheter Cardiovasc Interv; 2017 Jan; 89(1):1-10. PubMed ID: 27515100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of a Simple Angiographic Approach With a Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery Score-Based Approach for Left Main Coronary Artery Stenting: A Pooled Analysis of Serial PRECOMBAT (Premier of Randomized Comparison of Bypass Surgery Versus Angioplasty Using Sirolimus-Eluting Stent in Patients With Left Main Coronary Artery Disease) Studies.
    Lee PH; Lee JY; Lee CW; Kim SO; Ahn JM; Park DW; Kang SJ; Lee SW; Kim YH; Park SW; Park SJ
    Circ Cardiovasc Interv; 2018 Jan; 11(1):e005374. PubMed ID: 29311287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coronary Artery Bypass Graft Surgery and Percutaneous Coronary Interventions in Patients With Unprotected Left Main Coronary Artery Disease.
    Zheng Z; Xu B; Zhang H; Guan C; Xian Y; Zhao Y; Fan H; Yang Y; Wang W; Gao R; Hu S
    JACC Cardiovasc Interv; 2016 Jun; 9(11):1102-11. PubMed ID: 27282597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials.
    Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Melgares R; Mainar V; Moreno R; Domínguez A; Sanchís J; Bethencourt A; Moreu J; Cequier A; Martí V; Otaegui I; Bastante T; Gonzalo N; Jiménez-Quevedo P; Cárdenas A; Fernández C;
    Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 10-month angiographic and 4-year clinical outcome of everolimus-eluting versus sirolimus-eluting coronary stents in patients with diabetes mellitus (the DiabeDES IV randomized angiography trial).
    Maeng M; Baranauskas A; Christiansen EH; Kaltoft A; Holm NR; Krusell LR; Ravkilde J; Tilsted HH; Thayssen P; Jensen LO
    Catheter Cardiovasc Interv; 2015 Dec; 86(7):1161-7. PubMed ID: 25640050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the Efficacy of Paclitaxel-Eluting Balloon Catheters and Everolimus-Eluting Stents in the Treatment of Coronary In-Stent Restenosis: The Treatment of In-Stent Restenosis Study.
    Pleva L; Kukla P; Kusnierova P; Zapletalova J; Hlinomaz O
    Circ Cardiovasc Interv; 2016 Apr; 9(4):e003316. PubMed ID: 27069104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
    Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D
    JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials.
    Cassese S; Kufner S; Xhepa E; Byrne RA; Kreutzer J; Ibrahim T; Tiroch K; Valgimigli M; Tölg R; Fusaro M; Schunkert H; Laugwitz KL; Mehilli J; Kastrati A
    Clin Res Cardiol; 2016 Jul; 105(7):575-84. PubMed ID: 26689707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between the NERS (New Risk Stratification) score and the SYNTAX (Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) score in outcome prediction for unprotected left main stenting.
    Chen SL; Chen JP; Mintz G; Xu B; Kan J; Ye F; Zhang J; Sun X; Xu Y; Jiang Q; Zhang A; Stone GW
    JACC Cardiovasc Interv; 2010 Jun; 3(6):632-41. PubMed ID: 20630456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiographic and clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine clinical practice: Results of the ISAR-ABSORB registry.
    Hoppmann P; Kufner S; Cassese S; Wiebe J; Schneider S; Pinieck S; Scheler L; Bernlochner I; Joner M; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA
    Catheter Cardiovasc Interv; 2016 Apr; 87(5):822-9. PubMed ID: 26708019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravascular ultrasound assessment of optimal stent area to prevent in-stent restenosis after zotarolimus-, everolimus-, and sirolimus-eluting stent implantation.
    Song HG; Kang SJ; Ahn JM; Kim WJ; Lee JY; Park DW; Lee SW; Kim YH; Lee CW; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2014 May; 83(6):873-8. PubMed ID: 22815193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Post-Dilatation Following Primary PCI With Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: An Angiographic and Optical Coherence Tomography TROFI II Substudy.
    Yamaji K; Brugaletta S; Sabaté M; Iñiguez A; Jensen LO; Cequier A; Hofma SH; Christiansen EH; Suttorp M; van Es GA; Sotomi Y; Onuma Y; Serruys PW; Windecker S; Räber L
    JACC Cardiovasc Interv; 2017 Sep; 10(18):1867-1877. PubMed ID: 28935079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.